OCTOPUS, an optimized device for growing mini-organs in a dish
Engineers create device enabling intestinal organoids to develop to unprecedented levels of maturity
Peer-Reviewed PublicationWhen it comes to human bodies, there is no such thing as typical. Variation is the rule. In recent years, the biological sciences have increased their focus on exploring the poignant lack of norms between individuals, and medical and pharmaceutical researchers are asking questions about translating insights concerning biological variation into more precise and compassionate care.
What if therapies could be tailored to each patient? What would happen if we could predict an individual body’s response to a drug before trial-and-error treatment? Is it possible to understand the way a person’s disease begins and develops so we can know exactly how to cure it?
Dan Huh, Associate Professor in the Department of Bioengineering at the University of Pennsylvania’s School of Engineering and Applied Science, seeks answers to these questions by replicating biological systems outside of the body. These external copies of internal systems promise to boost drug efficacy while providing new levels of knowledge about patient health.
An innovator of organ-on-a-chip technology, or miniature copies of bodily systems stored in plastic devices no larger than a thumb drive, Huh has broadened his attention to engineering mini-organs in a dish using a patient’s own cells.
A recent study published in Nature Methods helmed by Huh introduces OCTOPUS, a device that nurtures organs-in-a-dish to unmatched levels of maturity. The study leaders include Estelle Park, doctoral student in Bioengineering, Tatiana Karakasheva, Associate Director of the Gastrointestinal Epithelium Modeling Program at Children’s Hospital of Philadelphia (CHOP), and Kathryn Hamilton, Assistant Professor of Pediatrics in Penn’s Perelman School of Medicine and Co-Director of the Gastrointestinal Epithelial Modeling Program at CHOP.
In the study, the team used OCTOPUS (Organoid Culture-based Three-dimensional Organogenesis Platform with Unrestricted Supply of soluble signals) to learn more about the unique challenges faced by children suffering with Inflammatory Bowel Disease (IBD).
“The aim of this research,” says Park, “is to create devices that give cells an environment as close as possible to the human body. We want their development in the dish to match the development of their source, so we have a true copy to learn from. In a world where more than 90 percent of pre-clinical animal studies fail before testing on human subjects, and the ethics of both are complex, OCTOPUS will be an invaluable addition to current laboratory practice.”
First developed in 2009, these organs-in-a-dish, known as “organoids,” opened doors to major improvements in medical research and patient care.
To make them, scientists collect organ-specific stem cells and introduce them into a droplet of three-dimensional gel. Nourished by a carefully developed chemical diet, the stem cells spontaneously organize themselves into an immature organ.
Compared to the simple two-dimensional cell cultures that form the backbone of laboratory testing, organoids hold a trove of information. Organs are made of up a variety of cell types, and these cells are more than the sum of their biological materials. They develop and function in communication with one another.
Organoids, unlike traditional cell cultures, allow these relationships to develop. They provide powerful tools for studying how organs develop and carry out their specialized functions.
Generating a wealth of difficult-to-access data about human bodies, organoids reproduce both healthy and abnormal aspects of individual patients’ organs. The more mature the organoid, the more they approximate the true complexity of the organ.
With OCTOPUS, Huh’s team has significantly advanced the frontiers of organoid research, providing a platform superior to the conventional gel droplets.
OCTOPUS splits the soft hydrogel culture material into a tentacled geometry. The thin, radial culture chambers sit on a circular disk the size of a U.S. quarter, allowing organoids to advance to an unprecedented degree of maturity.
“Limited tissue maturity is a significant problem in organoid and stem cell research,” says Huh.
“Efforts to address the issue have focused primarily on biochemistry by developing better media formulations that help stem cells differentiate into more mature tissues. As engineers, we tackled this problem from a different perspective by paying more attention to the physical aspects of how organoids grow. Redesigning the three-dimensional geometry of the hydrogel scaffold, we were able to engineer the biochemical environment of conventional culture models. OCTOPUS improves the transport of nutrients, oxygen, and growth factors without reformulating media biochemistry at all.”
The paper also introduces an enhanced version of the platform, called OCTOPUS-EVO, which takes maturity to the next level. Transforming the insert into a compartmentalized device with precise control of its fluid environment, Huh’s team used a variety of organ cell types to create organoids so advanced they developed functional blood vessels.
“The beauty of our technology,” says Huh, “is its minimalism. We designed the device with usability foremost in our minds. A simple insert, OCTOPUS can be effortlessly incorporated into existing laboratory techniques. The technology is easy to adopt and ready to make an immediate impact.”
Hamilton, whose lab currently uses OCTOPUS to grow organoids to study children’s gut diseases, describes the devices as transformative.
“The better medical researchers can faithfully reproduce the way the organ acts in the body, the better they can predict a patient’s response,” says Hamilton. “This technology is exactly what we need to screen drugs, test therapies, describe healthy behaviors and locate dysfunction. We’re learning new things every day.”
JOURNAL
Nature Methods
ARTICLE TITLE
Geometric engineering of organoid culture for enhanced organogenesis in a dish
COI STATEMENT
D.D.H. is a cofounder of Vivodyne Inc. and holds equity in Vivodyne Inc. and Emulate Inc. The remaining authors declare no competing interests.
No comments:
Post a Comment